Knockdown of SFRP2 suppresses the proliferation of pulmonary artery fibroblasts and the progression of apoptosis resistance, suggesting that SFRP2 may serve as a potential therapeutic target for PAH. This evidence concerns the gene SFRP2 and pulmonary arterial hypertension.